Search
for
Sort by
Research 91–120 of 313
- Treating Psoriasis: What Is New About Fumaric Acid Esters?
- HAIR FOLLICLE STEM CELLS IN THE PATHOGENESIS OF PRIMARY CICATRICIAL ALOPECIA
- Clinical Management in Psychodermatology
- Evaluation of dry eye and Meibomian gland dysfunction in female androgenetic alopecia patients
- Incidence of adverse cutaneous drug reactions in a Mexican sample: an exploratory study on their association to tumour necrosis factor alpha TNF2 allele
- Tufted Hair Folliculitis Decalvans as a Clinical Diagnostic Sign
- New treatment modalities of alopecia areata
- AN SYNOPTIC OVERVIEW ON AUTOIMMUNE DISORDERS AND ITS MANAGEMENT
- Cutaneous manifestations of metabolic diseases: uncommon presentations
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- The Contributory Roles of Th17 Lymphocyte and Cytotoxic T Lymphocyte at the Hair Bulge Region as Well as the Hair Bulb Area in the Chronic Alopecia Areata Patients
- Skin Manifestations of Targeted Antineoplastic Therapy
- Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints
- New Modalities in the Treatment of Refractory Alopecia Areata
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- 068 Pathogenic Th17 cells, CD8+CD69+CD49a- tissue-resident memory T cells and common γ chain receptor + natural killer cells express more IL-17, compared to IFN-γ, under the foxp3+ memory regulatory T cells-depleted microenvironment in patients with chronic alopecia areata
- Cutaneous and Mucosal Lichen Planus: A Comprehensive Review of Clinical Subtypes, Risk Factors, Diagnosis, and Prognosis
- Sebaceous Gland Atrophy in Psoriasis: An Explanation for Psoriatic Alopecia?
- Trichohyalin is a Potential Major Autoantigen in Human Alopecia Areata
- Pathophysiology of the Behçet's Disease
- Chronic graft versus host disease and skin
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- In vivo response of GsdmA3Dfl/+ mice to topically applied anti-psoriatic agents: effects on epidermal thickness, as determined by optical coherence tomography and H&E staining
- Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Chikungunya virus infection in the skin: histopathology and cutaneous immunological response
- Evaluation of Serum Inflammatory Markers and Their Relationship to Treatment Response in Alopecia Areata Patients
- Common contact allergens implicated in frontal fibrosing alopecia found in over-the-counter hair growth serums and solutions
- Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure